LabTurbo Biotech (7725.TWO) Akcie Kurz

LabTurbo Biotech Corp generates revenue through its fully automated precision medical genetic testing systems and reagent kits, sold domestically and internationally. The company offers the LabTurbo AIO device for nucleic acid extraction, alongside nucleic acid extraction reagents and multi-specimen genetic testing reagents. Its testing services and sports science centers also contribute to revenue streams. Domestic and international customers purchase these products and services for medical and sports science applications. The firm's primary products are LabTurbo AIO, nucleic acid extraction reagents, and multi-specimen genetic testing reagents. These are sold to healthcare providers, laboratories, and sports science centers. The company's international sales target global healthcare markets, while domestic sales focus on Taiwan's health sector. Testing services are provided to clients seeking genetic analysis without purchasing equipment. LabTurbo Biotech Corp's revenue model combines hardware sales, consumable reagents, and service offerings. The LabTurbo AIO device is a key hardware product, while reagents represent recurring revenue through repeat purchases. Testing services cater to clients needing immediate genetic analysis, and sports science centers operate as a separate revenue stream within the company's diversified business.